SIA
PVCT

Stancorp Investment Advisers’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Stancorp Investment Advisers’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$11K Hold
14,000
– – 0.01% 446
2014
Q4 		$11K Buy
+14,000
New +$12.8K 0.01% 425

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Stancorp Investment Advisers's PVCT Position: Q1 2015 in Review

Stancorp Investment Advisers held its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) position steady in Q1 2015 at 14,000 shares worth $11K. The position accounts for 0.01% of the portfolio, ranked #446.

Stancorp Investment Advisers first reported a position in PVCT in Q4 2014 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold PVCT as of Q1 2015.

  • Stancorp Investment Advisers held 14,000 shares of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) worth $11K as of Q1 2015.
  • Stancorp Investment Advisers left its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) share count unchanged in Q1 2015.
  • PROVECTUS BIOPHARMACEUTICALS, INC. (DE) made up 0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #446 holding.
  • Stancorp Investment Advisers first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.